Summary
In this small phase 2 study, 60% of patients with stage IIIA non–small cell lung cancer with known EGFR mutations (exon 19 or exon 21) were able to proceed to radical resection. The ultimate long-term outcomes associated with this strategy are still undetermined.
- phase 2
- single-arm
- non–small cell lung cancer
- neoadjuvant erlotinib
- radical resection
- carcinoembryonic antigen
- EGFR mutation
- exon 19
- exon 21
- NCT01217619
- oncology clinical trials
- adjuvant/neoadjuvant therapy
- © 2015 SAGE Publications
Tools
Table of contents
Cited By...
- No citing articles found.